Venous thromboembolic events seemed to be more frequent with anti-TNF-α than with tofacitinib (0.16 (95% CI, 0.04–0.41) vs. 0.54 (95% CI, 0.30–0.89) for PE and 0.04 (95% CI, 0.00–0.23) vs. 1.41 (95% CI, 1.00–1.93) for DVT) [64]. This evidence concerns the gene TNF and deep vein thrombosis.